Market Research Report
Big Data and AI in Market Access
|Big Data and AI in Market Access|
Published: November 6, 2020
Delivery time: 1-2 business days
Juggling the demands of multiple stakeholders for evidence of utility and value, while harnessing the insights from an ever-growing number of diverse data sources, has created a mounting workload for market access teams-and COVID-19 has not helped. To ease the pressure, many companies have implemented artificial intelligence (AI) and machine learning technologies to process big data sets. Outcomes have seen faster analysis of clinical trial data, identification of RWE gaps and the agile generation of evidence to meet HTA and other stakeholder requirements. So, what's next for advanced AI analytics and what key trends should market access planners be following?
To examine in detail this critical area of pharma's business we interviewed pharma and market access experts. In ‘Big Data and AI in Market Access ’they reveal the applications and strategies that are delivering clinical, operational and commercial wins across the market access spectrum.